Ivan Foeldvari is an expert in Rheumatology at Schön Klinik Hamburg Eilbek (Germany). As of June 2026, ScienceLeadR ranks Ivan Foeldvari in the top 1% of experts worldwide for Arthritis and Autoimmune Diseases. Ivan Foeldvari has authored 392 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 1 of them ongoing. SLR score: 1,224 (community average: 125). How the SLR is computed.

LeadR Profile

Ivan Foeldvari Schön Klinik Hamburg Eilbek Germany
1 224 ScienceLeadR Reputation 1224
Network Map

Rheumatology

Subspecialties: Immunology - Dermatology - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

I have a lifetime interest in pediatric rheumatology. I begin to be interested in juvenile sclerosis during my fellowship in Vancouver. I had one of my first ACR Congress Posters with Prof Tom Lehman from Cornell University in New York USA. I conducted a cross sectional multinational survey of clinical features, which was published 2000, containing the largest number of patients ever surveyed. I am founding member of the juvenile scleroderma working group of the Pediatric Rheumatology European Society and was leader for several years I am lead of the clinical affairs of the juvenile scleroderma working group of the Pediatric Rheumatology European Society since 2023. I am member of EUSTAR and leading the pediatric working group of the Scleroderma Clinical Trial Consortium. I am the PI and founder of the Juvenile Scleroderma Inception Cohort, which is currently the largest cohort of juvenile Systemic Scleroderma in the world.

I am organizing the annual Hamburg meeting regarding juvenile Scleroderma for the last 18 years.Based on these meetings we published guidance for juvenile localized scleroderma, Raynaud’s in children and juvenile systemic scleroderma assessment and treatment. I was part of the SHARE initiative for juvenile systemic scleroderma and I am the first author of the guidance publication for “best treatment” and for stemm cell therapy.

Our center is one of the leading centers in Europe for Phase II, III and IV studies regarding upcoming new medications for juvenile systemic sclerosis, juvenile idiopathic arthritis and JIA associated uveitis.


Organizations

Career arc: 1995 - 2026

Source: PubMed

Schön Klinik Hamburg Eilbek

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 392

Citations

Citations: 12 472 1st author: 90 Last author: 21 Unique author: 23


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.
PMID 42247287 — sclerosis, immune system diseases, scleroderma, systemic
Expert Rev Clin Immunol20260
Serological biomarkers of JIA-associated uveitis: ANA titers, ANA AC-30 staining pattern and prefoldin 5 antibodies.
PMID 42192482 — autoantibodies, serum, antibodies, arthritis, biomarkers, uveitis
Arthritis Res Ther20260
What is the best way to plan a 12-months clinical drug trial in JIA associated uveitis.
PMID 42084907 — cells, uveitis, anterior, pharmaceutical preparations, biomarkers, tomography, optical coherence, arthritis, juvenile, uveitis, anterior chamber
Expert Rev Clin Immunol20260
Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept.
PMID 42011511 — arthritis, rheumatic diseases, etanercept, arthritis, juvenile, child, age of onset
Rheumatology (Oxford)20260
Emotional well-being at diagnosis may indicate future mental health risk in patients with juvenile idiopathic arthritis: data from the German inception cohort ICON.
PMID 41956707 — patient health questionnaire, quality of life, arthritis, rheumatic diseases, signs and symptoms, diagnosis, therapeutics, arthritis, juvenile, mental health
RMD Open20260

Clinical Studies 18

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

N/A 8
Phase 3 8
Phase 1 1
Phase 1/Phase 2 1

By status:

Completed 8
Unknown 6
Active not recruiting 2
Recruiting 1
Terminated 1

By type:

Interventional 10
Observational 8

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 14

Main Topics

Cohort/Consortium Investigators 10

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT04527380 — arthritis, psoriatic, safety, spondylitis, ankylosing, arthritis, spondylitis, adalimumab, arthritis, juvenile, child
Phase 3Active not recruiting2021

LeadR Networks

Main global connection map